Hy Isenbaum

Telesta Therapeutics, Inc. is a biotechnology company, which focuses on the licensing/acquisition and development of transformational therapeutics for the treatment of serious human diseases, such as cancer, immune diseases, and targeted rare diseases. The company was founded by Graeme McRae in 1979 and is headquartered in Pointe-Claire, Canada.

Lunenfeld-Tanenbaum Research Institute engages in the provision of biomedical research services. It conducts research into various forms of cancer including colon, breast, pancreatic, prostate, neurological disorders and brain illnesses, women's and infants' health, diabetes, developmental biology, stem cell biology and tissue regeneration, mouse models of human disease, genomic medicine, and systems biology. The company was founded in 1985 and is headquartered in Toronto, Canada.